Current Oncology

Established in 1994, Current Oncology is a peer-reviewed, Canadian based and Internationally distributed journal. Published bi-monthly plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is published by Multimed Inc.

Current Oncology is indexed/covered in PubMed, EMBASE (Excerpta Medica Database), Scopus, Journal Selector, CrossRef, Index Copernicus, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC), the U.S. National Library of Medicine's digital archive of biomedical and life sciences journal literature. It is also available in the databases of 100 libraries worldwide, and is a participant of the HINARI program.

The information provided on the Current Oncology website is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.



Journal Announcement: New Impact Factor of 1.785 for Current Oncology!


We are pleased to announce to our readers that Current Oncology’s 2014 Impact Factor has increased to 1.785! This is an increase from our 2014 stats, where we received an impact factor of 1.643.

The journal impact factor is a measure of citation frequency that reflects the average number of citations to articles published in science and social science journals. Impact factors are calculated annually for those journals that are indexed in Thomson Reuters Journal Citation Reports. The impact factor of a journal in a given year is the average number of citations a paper published in that journal received during the two previous years. The impact factor is often used to rank the relative importance and scientific caliber of a journal within its field.

Our 2014 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for their valuable contribution to the journal. We look forward to continued success in 2015 as the journal continues to strengthen and grow!

Multimed Inc.
Publisher of Current Oncology

Posted: 2015-06-25 More...

Journal Announcement: Call for Papers: Clinical Research and Clinical Trials


Current Oncology is seeking high-quality original clinical research and clinical trial articles. Areas may include research related to treatment, prevention, diagnostic, screening, and quality of life. Articles submitted should contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.

To help encourage submissions, Current Oncology will waive Standard Author Fees for all original clinical research and clinical trial articles, submitted between July 1st and December 31st, 2015.

View full announcement here.

Posted: 2015-06-23 More...

Health Canada Approves New Treatment ZYDELIG (idelalisib) For Two Incurable Blood Cancers


Health Canada has approved a new treatment option for relapsed patients with chronic lymphocytic leukemia (CLL) and for follicular lymphoma (FL).  Gilead Sciences Canada’s ZYDELIG™ (idelalisib) tablets, received a Notice of Compliance in combination with rituximab for the treatment of patients with relapsed CLL.  ZYDELIG also received a Notice of Compliance with Conditions as a stand-alone treatment for patients with FL who have undergone at least two prior systemic regimens and are resistant to both rituximab and an alkylating agent.  

CLL and FL are slow-growing incurable blood cancers, most common in adults 50 years of age and older, that can lead to life-threatening complications such as anemia, serious infection and bone marrow failure requiring treatment.  As conventional chemotherapy is not curative for CLL or FL, nearly all patients will eventually relapse after their initial treatment.  At relapse, patients often face fewer treatment options because they may be unable to tolerate chemotherapy, or become resistant to treatment.

“Idelalisib offers an important treatment option for Canadians living with CLL and FL at the time of relapse,” said Dr. Carolyn Owen, Assistant Professor, Division of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary.  “With these cancers, relapsed patients are often unable to tolerate traditional chemotherapy and thus, they require new active treatment options, particularly if several other therapies have failed.  Many of these patients have previously had limited, if any, treatment options.  We are now entering a new era of management of CLL and FL patients.  In the pivotal CLL clinical study, idelalisib demonstrated a statistically significant improvement in progression-free survival.”

ZYDELIG is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that plays a role in the activation, proliferation and viability of B cells, a critical component of the immune system.  PI3K delta signaling is active in many B-cell leukemias and lymphomas.  By inhibiting the protein this blocks several cellular signaling pathways that drive B-cell viability.


Posted: 2015-06-18 More...
More Announcements...

Vol 22, No 3 (2015)

Cover Page

Outlook on Life

Mixed media by a person diagnosed with cancer, Quebec

I arrived almost at the end of my treatment and I will need an operation to reverse the intestinal stoma.

I painted this painting from a photo I had taken shortly before being diagnosed with cancer. I was very sick and I did not know then if I would have a chance to revisit or even paint these beautiful places that are for me a source of life and inner peace.

So, this painting symbolizes to me the inner strength that gave me the courage to fight and to cross towards the light on this little bridge which, like me, seemed so fragile.

The mixed media artwork on the cover of this issue is titled “Outlook on Life” and is by a person diagnosed with cancer from the 2014 Lilly Oncology On Canvas Canada art competition.

Oncology On CanvasSM is an art competition and exhibition that honours the journeys people face when confronted with a cancer diagnosis. This biennial competition invites individuals diagnosed with any type of cancer—as well as their families, friends, caregivers and healthcare providers—to express, through art and narrative, the life-affirming changes that give their cancer journeys meaning.

Oncology On Canvas was started in 2004 by Lilly Oncology to help address a great, unmet need in cancer care—a need that goes beyond medicine—to help those affected by cancer cope with the emotional toll of the disease. Since 2004, the National Coalition for Cancer Survivorship (NCCS) has been the co-presenter of the Lilly Oncology On Canvas Art Competition and Exhibition for US and Puerto Rico residents.

Lilly Oncology on Canvas Canada launched in 2014. Visit to learn more about the competition. Lilly Oncology on Canvas Canada is presented in partnership with the Canadian Association for Psychosocial Oncology and the Canadian Cancer Survivor Network.

Current Oncology is committed to the Canadian oncology community as well as oncology communities around the world. We are pleased to help raise awareness of this great program created by Lilly. Current Oncology will be selecting new artwork for each cover from previous competitions.

Artwork from the Canadian competition is available for viewing at Artwork from the US competition is available for viewing at

Copyright © 2015 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)